P
Parabolic Drugs
PARABDRUGS
Parabolic Drugs
Healthcare Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
1- Company has low interest coverage ratio.
Growth Rate
Revenue Growth
-100%
Net Income Growth
12% lower than
3Y
Quarterly Results
| Particulars | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16.39 | 16.23 | 12.85 | 4.97 | 0.26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 20.89 | 19.37 | 17.71 | 10.9 | 2.27 | 1.95 | 1.95 | 1.71 | 1.71 | 1.71 | 1.71 | 0.44 | 0.84 |
| Operating Profit | -4.5 | -3.14 | -4.86 | -5.93 | -2.01 | -1.95 | -1.95 | -1.71 | -1.71 | -1.71 | -1.71 | -0.44 | -0.84 |
| OPM % | -27.46% | -19.35% | -37.82% | -119.32% | -773.08% | — | — | — | — | — | — | — | — |
| Other Income | -0.04 | 0.02 | 0.13 | 0.66 | 0.01 | -1.88 | 0.01 | 0 | 0 | 0 | 0 | 0.27 | 0.23 |
| Interest | 1.9 | 2.09 | 1.26 | 2.7 | 0.05 | -0.54 | 0.16 | 0.17 | 0.17 | 0.17 | 0.17 | 0.46 | 0.34 |
| Depreciation | 8.65 | 8.59 | 5.73 | 5.67 | 5.14 | 5.97 | 5.56 | 5.34 | 5.34 | 5.34 | 5.34 | 4.85 | 5.1 |
| PBT | -15.09 | -13.8 | -11.72 | -13.64 | -7.19 | -9.26 | -7.66 | -7.22 | -7.22 | -7.22 | -7.22 | -5.48 | -6.05 |
| Tax % | 2.58% | 3.41% | -10.24% | 5.21% | -1.39% | 1.84% | -2.22% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -15.48 | -14.27 | -10.52 | -14.35 | -7.09 | -9.43 | -7.49 | -7.22 | -7.22 | -7.22 | -7.22 | -5.48 | -6.05 |
| EPS in Rs | -2.5 | -2.31 | -1.7 | -2.32 | -1.15 | -1.52 | -1.21 | -1.17 | -1.17 | -1.17 | -1.17 | -0.89 | -0.98 |
Profit & Loss
| Particulars | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 395 | 513 | 617 | 919 | 763 | 438 | 231 | 75 | 73 | 71 | 18 | 0 | 0 |
| Expenses | 335 | 430 | 515 | 762 | 836 | 519 | 310 | 381 | 118 | 87 | 33 | 6 | 5 |
| Operating Profit | 60 | 83 | 102 | 157 | -73 | -82 | -78 | -306 | -46 | -15 | -15 | -6 | -5 |
| OPM % | 15% | 16% | 17% | 17% | -10% | -19% | -34% | -410% | -62% | -22% | -82% | — | — |
| Other Income | 2 | 5 | 15 | 4 | 6 | 13 | 1 | 0 | 4 | 4 | -1 | 0 | 0 |
| Interest | 28 | 38 | 41 | 64 | 73 | 83 | 99 | 108 | 10 | 9 | 3 | 1 | 1 |
| Depreciation | 4 | 6 | 8 | 31 | 55 | 68 | 73 | 67 | 53 | 35 | 23 | 22 | 21 |
| PBT | 30 | 44 | 69 | 66 | -195 | -220 | -249 | -481 | -105 | -55 | -42 | -29 | -26 |
| Tax % | 20% | 22% | 23% | 23% | -28% | -40% | 52% | 1% | 3% | 3% | -1% | 0% | — |
| Net Profit | 24 | 34 | 53 | 51 | -140 | -132 | -379 | -485 | -108 | -57 | -41 | -29 | -26 |
| EPS in Rs | — | — | 8.54 | 8.27 | -22.58 | -21.28 | -61.29 | -78.39 | -17.46 | -9.21 | -6.69 | -4.63 | -4.21 |
| Div. Payout % | 0% | 0% | 6% | 3% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 37 | 62 | 62 | 62 | 62 | 62 | 62 | 62 | 62 | 62 | 62 | 62 |
| Reserves | 89 | 121 | 317 | 367 | 239 | 121 | -258 | -743 | -851 | -908 | -949 | -977 | -990 |
| Borrowings | 289 | 421 | 474 | 555 | 777 | 842 | 957 | 972 | 979 | 984 | 985 | 157 | 158 |
| Other Liabilities | 121 | 111 | 214 | 331 | 161 | 202 | 189 | 287 | 303 | 281 | 275 | 1,108 | 1,109 |
| Total Liabilities | 510 | 690 | 1,067 | 1,314 | 1,239 | 1,227 | 950 | 577 | 493 | 419 | 372 | 349 | 339 |
| Fixed Assets | 97 | 130 | 163 | 188 | 334 | 331 | 395 | 371 | 349 | 326 | 298 | 278 | 267 |
| CWIP | 19 | 41 | 112 | 187 | 72 | 81 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Investments | 2 | 2 | 6 | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Other Assets | 392 | 517 | 786 | 936 | 827 | 809 | 542 | 193 | 132 | 80 | 62 | 59 | 59 |
| Total Assets | 510 | 690 | 1,067 | 1,314 | 1,239 | 1,227 | 950 | 577 | 493 | 419 | 372 | 349 | 339 |
Cash Flow
| Particulars | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -40 | -31 | 3 | 207 | -111 | 28 | -4 | 90 | 2 | 3 | — | — |
| Investing | -56 | -87 | -180 | -205 | -108 | -30 | -16 | 1 | 0 | 1 | — | — |
| Financing | 103 | 122 | 186 | 7 | 197 | -4 | 17 | -93 | -2 | -4 | — | — |
| Net Cash Flow | 6 | 4 | 8 | 9 | -23 | -6 | -3 | -2 | 0 | 0 | — | — |
| Free Cash Flow | -87 | -91 | -110 | 97 | -158 | 3 | -17 | 91 | 2 | 4 | — | — |
| CFO/OP | -67 | -28 | 17 | 140 | 151 | -1 | 5 | -29 | -4 | -20 | — | — |
Ratios
| Particulars | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 135 | 137 | 163 | 88 | 66 | 124 | 155 | 342 | 335 | 148 | 562 | — |
| Inventory Days | 234 | 239 | 276 | 237 | 167 | 363 | 450 | 45 | 61 | 91 | 12 | — |
| Days Payable | 123 | 82 | 137 | 149 | 59 | 187 | 146 | 104 | 420 | 465 | 1,325 | — |
| Cash Conversion Cycle | 246 | 294 | 302 | 176 | 174 | 301 | 460 | 283 | -24 | -226 | -751 | — |
| Working Capital Days | 225 | 255 | 50 | 5 | 36 | 45 | -169 | -1,708 | -1,483 | -1,620 | -6,735 | — |
| ROCE % | 19% | 17% | 15% | 14% | -12% | -13% | -17% | -71% | -39% | -28% | -31% | — |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Parabolic Drugs insights
66 extracted metrics + investor summaries across FY09–FY20.
Documents
3
Corporate Insolvency Resolution Process (CIRP)-Public Announcement
8 Feb 2021 - This is in reference to the captioned matter and as per the Resolution Plan approved by Hon'ble National Company Law Tribunal, Chandigarh Bench ('NCLT') in … 8 Feb 2021 - This is in reference to the captioned matter and as per the Resolution Plan approved by Hon'ble National Company Law Tribunal, Chandigarh Bench ('NCLT') in …
4
Corporate Insolvency Resolution Process (CIRP)-Public Announcement
8 Feb 2021 - In reference to the captioned matter and as per the Resolution Plan approved by Hon'ble National Company Law Tribunal, Chandigarh Bench ('NCLT') in terms of … 8 Feb 2021 - In reference to the captioned matter and as per the Resolution Plan approved by Hon'ble National Company Law Tribunal, Chandigarh Bench ('NCLT') in terms of …
Frequently Asked Questions about Parabolic Drugs
What does Parabolic Drugs Ltd do?
Parabolic Drugs engages in the manufacture and contract manufacture of active pharmaceutical ingredients (API) and API intermediates.
Which sector does Parabolic Drugs Ltd belong to?
Parabolic Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Parabolic Drugs engages in the manufacture and contract manufacture of active pharmaceutical ingredients (API) and API intermediates.
Website parabolicdrugs.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PARABDRUGS.md for Parabolic Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.